AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31413691 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with irrigation and debridement
Number of subjects: 46
Study 31413691 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with antibiotics and wound care
Number of subjects: 46
Study 27443414 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 (n=80)
Number of subjects: 112
Study 27443414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=32)
Number of subjects: 112
Study 25026454 — intervention group
Group type: COMPARATOR
Intervention: 5LEU (23/5/180/30 g of protein/leucine/carbohydrate/fat)
Number of subjects: 12
Study 25026454 — intervention group
Group type: EXPERIMENTAL
Intervention: 15LEU (70/15/180/30 g of protein/leucine/carbohydrate/fat)
Number of subjects: 12
Study 25026454 — intervention group
Group type: COMPARATOR
Intervention: CON (0/0/274/30 g of carbohydrate/fat)
Number of subjects: 12
Study 25026454 — intervention group
Group type: EXPERIMENTAL
Intervention: 15LEU
Number of subjects: 12
Study 23852069 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc and Pathfile
Number of subjects: 88
Study 23852069 — intervention group
Group type: COMPARATOR
Intervention: ProTaper and Pathfile
Number of subjects: 88
Study 23852069 — intervention group
Group type: COMPARATOR
Intervention: Rotary ProTaper
Number of subjects: 88
Study 22018535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 0
Study 19858413 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS EXPRESS paclitaxel‐eluting stents (PES)
Number of subjects: 464
Study 19858413 — intervention group
Group type: COMPARATOR
Intervention: EXPRESS bare metal stents (BMS)
Number of subjects: 464
Study 16925565 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Patients (SPs)
Number of subjects: 512
Study 16925565 — intervention group
Group type: COMPARATOR
Intervention: Nonstudy Patients (NSPs)
Number of subjects: 512
Study 14701969 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline
Number of subjects: 2
Study 14701969 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 2
Study 14701969 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 2
Study 11551141 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (CaCl2) 15 mg/kg b.w. administered intravenously
Number of subjects: 43
Study 11551141 — intervention group
Group type: COMPARATOR
Intervention: Disodium EDTA 5 mg/kg b.w. administered intravenously
Number of subjects: 43
Study 9381521 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen intervention in a specially furnished room
Number of subjects: 16
Study 9381521 — intervention group
Group type: COMPARATOR
Intervention: Standard activities in the living room (Control)
Number of subjects: 16
Study 8492923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise started 1 hour after LD ingestion
Number of subjects: 10
Study 8492923 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 10
Study 3794392 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB irradiation
Number of subjects: 0
Study 3794392 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation
Number of subjects: 0
Study 30374603 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D therapy
Number of subjects: 0
Study 30374603 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment in children
Number of subjects: 0
Study 28538134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day
Number of subjects: 120
Study 28538134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28538134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 120
Study 23838836 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-first approach without presurgical orthodontic treatment
Number of subjects: 56
Study 23838836 — intervention group
Group type: COMPARATOR
Intervention: Standard orthognathic surgery
Number of subjects: 56
Study 23013143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (16.5 ± 0.5% O(2))
Number of subjects: 11
Study 23013143 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 11
Study 23013143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (with drop in SpO(2) > 10%)
Number of subjects: 11
Study 23013143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia and exercise
Number of subjects: 11
Study 21825028 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of lower limb cast immobilisation
Number of subjects: 378
Study 18496276 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocontrol Biofeedback System (HBS)
Number of subjects: 0
Study 18496276 — intervention group
Group type: COMPARATOR
Intervention: Best clinical practices
Number of subjects: 0
Study 16567837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2980
Study 16567837 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2980
Study 16567837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2980
Study 12394920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium release assay
Number of subjects: 20
Study 12394920 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric assay
Number of subjects: 20
Study 10439008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential PCRs (group I, n = 30)
Number of subjects: 58
Study 10439008 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed in situ labeling (PRINS) before five sequential PCRs (group II, n = 10)
Number of subjects: 58
Study 10439008 — intervention group
Group type: EXPERIMENTAL
Intervention: Staining with hematoxylin before performing five sequential PCRs (group III, n = 11)
Number of subjects: 58
Study 10439008 — intervention group
Group type: EXPERIMENTAL
Intervention: Preamplification of whole DNAs by degenerate oligonucleotide primer (DOP) before performing PCR (group IV)
Number of subjects: 58
Study 7995742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (120 mg/kg) and total body irradiation (1320 Gy in eight fractions over 4 days) (CY/TBI)
Number of subjects: 35
Study 7995742 — intervention group
Group type: COMPARATOR
Intervention: Busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) (BU/CY)
Number of subjects: 35
Study 7995742 — intervention group
Group type: EXPERIMENTAL
Intervention: CY/TBI
Number of subjects: 35
Study 7995742 — intervention group
Group type: COMPARATOR
Intervention: BU/CY
Number of subjects: 35
Study 2312805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine
Number of subjects: 10
Study 2312805 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 10
Study 375369 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioisotope synoviorthesis with 90Y (4 mCi)
Number of subjects: 0
Study 375369 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioisotope synoviorthesis with 198Au or 186Rh
Number of subjects: 0
Study 375369 — intervention group
Group type: COMPARATOR
Intervention: Saline + prednisolone acetate (control)
Number of subjects: 0
Study 31343196 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 912
Study 31343196 — intervention group
Group type: COMPARATOR
Intervention: Intensive Outpatient Treatment (IOP)
Number of subjects: 912
Study 29903423 — intervention group
Group type: EXPERIMENTAL
Intervention: xylazine and butorphanol administered intravenously (IV)
Number of subjects: 8
Study 29903423 — intervention group
Group type: EXPERIMENTAL
Intervention: detomidine and butorphanol administered IV
Number of subjects: 8
Study 29903423 — intervention group
Group type: EXPERIMENTAL
Intervention: xylazine administered IV and lidocaine topically
Number of subjects: 8
Study 29903423 — intervention group
Group type: EXPERIMENTAL
Intervention: detomidine administered IV and lidocaine topically
Number of subjects: 8
Study 29903423 — intervention group
Group type: COMPARATOR
Intervention: no analgesia or sedation (control)
Number of subjects: 8
Study 29903423 — intervention group
Group type: EXPERIMENTAL
Intervention: butorphanol
Number of subjects: 8
Study 26545288 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger Coping Programme based on cognitive behavioural techniques
Number of subjects: 62
Study 26545288 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 25298243 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous assisted approach
Number of subjects: 0
Study 25298243 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral approach
Number of subjects: 0
Study 22918856 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 250 mg metronidazole immediate release formulation
Number of subjects: 22
Study 22918856 — intervention group
Group type: COMPARATOR
Intervention: Reference 250 mg metronidazole immediate release formulation
Number of subjects: 22
Study 20150293 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet with resistance training (HP+RT)
Number of subjects: 83
Study 20150293 — intervention group
Group type: COMPARATOR
Intervention: Control diet with resistance training (CON+RT)
Number of subjects: 83
Study 20150293 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP)
Number of subjects: 83
Study 20150293 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 83
Study 20150293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reduction across all groups
Number of subjects: 83
Study 18160750 — intervention group
Group type: EXPERIMENTAL
Intervention: Category-1 regimen for PTB
Number of subjects: 278
Study 18160750 — intervention group
Group type: EXPERIMENTAL
Intervention: Category-1 regimen for DM-TB
Number of subjects: 278
Study 18160750 — intervention group
Group type: EXPERIMENTAL
Intervention: Category-1 regimen for HIV-TB
Number of subjects: 278
Study 16136943 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment group (radiotherapy + Chinese herbal drugs)
Number of subjects: 60
Study 16136943 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple radiotherapy)
Number of subjects: 60
Study 12396855 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 65
Study 12396855 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 65
Study 12396855 — intervention group
Group type: COMPARATOR
Intervention: General physicians
Number of subjects: 65
Study 10581644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 18
Study 10581644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine pretreatment
Number of subjects: 18
Study 10581644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study 7568433 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride treatment
Number of subjects: 0
Study 7568433 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic Na+ salts and Li+ salts
Number of subjects: 0
Study 7568433 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 0
Study 1970907 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 40
Study 1970907 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine 60 mg
Number of subjects: 40
Study 1970907 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg plus Pseudoephedrine 60 mg
Number of subjects: 40
Study 1970907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 91478 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse field stimulation in 44 MS patients
Number of subjects: 85
Study 91478 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of central and peripheral retina in 41 MS patients
Number of subjects: 85
Study 91478 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting of 20 subjects with normal/slightly altered full field VEPs
Number of subjects: 85
Study 91478 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CPLD with clinical involvement
Number of subjects: 85
Study 30824559 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM‐101/65 (65 mg carbidopa, 75-150 mg levodopa, 200 mg entacapone)
Number of subjects: 117
Study 30824559 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM‐101/105 (105 mg carbidopa, 75-150 mg levodopa, 200 mg entacapone)
Number of subjects: 117
Study 30824559 — intervention group
Group type: COMPARATOR
Intervention: LCE (standard combination of 4:1 levodopa/carbidopa with 200 mg entacapone)
Number of subjects: 117
Study 30824559 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM‐101/65
Number of subjects: 117
Study 30824559 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM‐101/105
Number of subjects: 117
Study 30824559 — intervention group
Group type: COMPARATOR
Intervention: LCE
Number of subjects: 117
Study 30824559 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM‐101/65 and ODM‐101/105
Number of subjects: 117
Study 28738338 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go test (TUG) real (TUGr)
Number of subjects: 52
Study 28738338 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go test (TUG) imagined (TUGi)
Number of subjects: 52
Study 28738338 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test part B (TMT B)
Number of subjects: 52
Study 28738338 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 52
Study 28738338 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test A/B ratio (TMT B/A)
Number of subjects: 52
Study 27451343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 683
Study 27451343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study 24092769 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (11.1g·kg‐1)
Number of subjects: 9
Study 24092769 — intervention group
Group type: COMPARATOR
Intervention: Calorie-matched low carbohydrate diet (2.1 g·kg‐1)
Number of subjects: 9
Study 22038392 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated QOL using the QOL-AD scale
Number of subjects: 254
Study 22038392 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-rated QOL-AD scores
Number of subjects: 254
Study 22038392 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-rated ADRQL scores
Number of subjects: 254
Study 19667948 — intervention group
Group type: COMPARATOR
Intervention: P/CsA
Number of subjects: 113
Study 19667948 — intervention group
Group type: COMPARATOR
Intervention: P/MPS
Number of subjects: 113
Study 19667948 — intervention group
Group type: COMPARATOR
Intervention: P/EVL
Number of subjects: 113
Study 17461874 — intervention group
Group type: EXPERIMENTAL
Intervention: Home orthostatic self-training (daily sessions for 7 days a week for 4 weeks)
Number of subjects: 42
Study 17461874 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 42
Study 17461874 — intervention group
Group type: EXPERIMENTAL
Intervention: Home orthostatic self-training
Number of subjects: 42
Study 15932835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 2.5 mg/d
Number of subjects: 497
Study 15932835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 5.0 mg/d
Number of subjects: 497
Study 15932835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 10 mg/d
Number of subjects: 497
Study 15932835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d
Number of subjects: 497
Study 15932835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 30 mg/d
Number of subjects: 497
Study 15932835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg/d
Number of subjects: 497
Study 15932835 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens (0.625 mg)/medroxyprogesterone acetate (2.5 mg) (active control)
Number of subjects: 497
Study 15932835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 11956508 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg bosentan twice a day for 10 days plus 2.5 mg glyburide twice a day on days 6 to 10
Number of subjects: 12
Study 11956508 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg glyburide twice a day for 10 days plus 125 mg bosentan twice a day on days 6 to 10
Number of subjects: 12
Study 9605682 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (anesthesia at 0.5, 1, and 1.5 MAC)
Number of subjects: 17
Study 9605682 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (anesthesia at 0.5, 1, and 1.5 MAC)
Number of subjects: 17
Study 1992536 — intervention group
Group type: COMPARATOR
Intervention: 7‐3 (cytarabine 100 mg/m2/d days 1 to 7 and daunorubicin 50 mg/m2/d days 1 to 3)
Number of subjects: 264
Study 1992536 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐3‐7 (7‐3 plus etoposide 75 mg/m2/d days 1 to 7)
Number of subjects: 264
Study 1992536 — intervention group
Group type: COMPARATOR
Intervention: 7‐3
Number of subjects: 264
Study 1992536 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐3‐7
Number of subjects: 264
Study 1992536 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐3 and 7‐3‐7
Number of subjects: 264
Study 6340300 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 250 mg i.v. 2 hours before cis-platinum administration
Number of subjects: 90
Study 6340300 — intervention group
Group type: COMPARATOR
Intervention: Torecan
Number of subjects: 90
Study 6340300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml saline)
Number of subjects: 90
Study 30829918 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Alcoholic Fatty Liver Disease (NAFLD)
Number of subjects: 324
Study 29367035 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolour inking (arm A)
Number of subjects: 50
Study 29367035 — intervention group
Group type: COMPARATOR
Intervention: Monocolour inking (arm B)
Number of subjects: 50
Study 29367035 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall R1 resection rate
Number of subjects: 50
Study 29367035 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior surface margin
Number of subjects: 50
Study 29367035 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior mesenteric artery margin
Number of subjects: 50
Study 29367035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic remnant margin
Number of subjects: 50
Study 27188899 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin supplementation at doses of 0.2, 0.4, 0.6, 0.8, or 1.0 mg daily for 6 weeks
Number of subjects: 78
Study 27188899 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin supplementation at doses of 0.6 mg/d and above
Number of subjects: 78
Study 27188899 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin supplementation
Number of subjects: 78
Study 23714686 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic syrup
Number of subjects: 80
Study 23714686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22486138 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative volume loading (lactated Ringer 10 ml/kg before induction of general anesthesia)
Number of subjects: 30
Study 22486138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative volume loading)
Number of subjects: 30
Study 20858770 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 199
Study 20858770 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 199
Study 18197496 — intervention group
Group type: EXPERIMENTAL
Intervention: Young group (under 40 years old)
Number of subjects: 301
Study 18197496 — intervention group
Group type: COMPARATOR
Intervention: Old group (over 65 years old)
Number of subjects: 301
Study 18197496 — intervention group
Group type: EXPERIMENTAL
Intervention: Young group (under 40 years old) with same TNM stage
Number of subjects: 301
Study 18197496 — intervention group
Group type: COMPARATOR
Intervention: Old group (over 65 years old) with same TNM stage
Number of subjects: 301
Study 16365696 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplemented (90 days' diet supplementation with 500 mg/day vitamin E and 30 mg/day beta‐carotene, and the last 15 days also with 1 g/day vitamin C)
Number of subjects: 15
Study 16365696 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 15
Study 16365696 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 15
Study 14629842 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 24
Study 14629842 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 24
Study 14629842 — intervention group
Group type: COMPARATOR
Intervention: Control (osteopathic knee care and education only)
Number of subjects: 24
Study 11127493 — intervention group
Group type: EXPERIMENTAL
Intervention: Swine dust exposure for 3 hours
Number of subjects: 17
Study 11127493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial histamine challenge
Number of subjects: 17
Study 9059094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximeter readings in patients with low systemic vascular resistance
Number of subjects: 80
Study 9059094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximeter readings in patients with normal or high systemic vascular resistance
Number of subjects: 80
Study 8363169 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of amikacin (20 mg/kg) and ceftriaxone (30 mg/kg for adults, 80 mg/kg for children)
Number of subjects: 677
Study 8363169 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily doses of amikacin (6.5 mg/kg every 8 hours) and ceftazidime (33 mg/kg every 8 hours)
Number of subjects: 677
Study 8363169 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of amikacin and ceftriaxone
Number of subjects: 677
Study 8363169 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily doses of amikacin and ceftazidime
Number of subjects: 677
Study 3539037 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold therapy
Number of subjects: 72
Study 3539037 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy (DPA)
Number of subjects: 72
Study 30552272 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Shared Decision-Making Programme (ISDM-P)
Number of subjects: 279